1. National Comprehensive Cancer Network®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.4.2021.© National Comprehensive Cancer Network, Inc. 202All rights reserved. (Accessed 05/05/2020). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
2. D. Planchard, S. Popat, K. Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. †Updated version published 15 September 2020 by the ESMO Guidelines Committee 2020 [updated 15/09/20. Available from: https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer. (Accessed 25/09/21).
3. D. Planchard, S. Popat, K Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2018;29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275.
4. Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines;Postmus;Ann. Oncol.,2017
5. N.I. Lindeman, P.T. Cagle, D.L. Aisner, M.E. Arcila, M.B. Beasley, E.H. Bernicker, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch. Pathol. Lab. Med. 2018;142(3):321–346. https://doi.org/10.5858/arpa.2017-0388-CP.